News

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

The new partnership will work to embed digital identification into labware, solving chain-of-identity challenges for individualized cell and gene therapies.

Real-world data can be utilized to ensure quality and effectiveness of drug products.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, Parexel, give their opinions on why those working in the pharmaceutical industry should lend their voices to draft regulations.

Non-parenteral alternatives for biologics remain a clinical imperative and a formidable challenge.

Recent developments show how innovations and treatments for cancer are rapidly advancing.

Major pharmaceutical investments in the United States are expanding API, capsule, and packaging capacity, enhancing supply chain resilience and supporting domestic drug production.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

In episode 27, Christopher Hopkins, PhD; Omkar Kawalekar, PhD; Barnaby Pickering; and Jerry Rosenbaum, MD, go behind the headlines.

Spotlighting global biopharma innovation, the event will unite leaders to discuss digitalization, sustainable manufacturing, and future-ready development.

The first needle-free adrenaline treatment launches in the UK, validating non-invasive delivery with real-world data comparable to injection effectiveness.

Take this quiz to test your comprehension of one of our recent feature articles.

As the conference approaches, scientists are reviewing new technologies that enhance manufacturing process control, product integrity, and regulatory compliance through automation and sustainable materials.

Biopharma R&D strategy pivots: M&A favors late-stage assets, obesity deals surge, AI accelerates manufacturing, and policy drives strategic US facility investment.

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

Advanced biotech equipment, driven by R&D investment and personalized medicine, is essential for scalable drug production and development into the next decade, according to a BCC Research report.

This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development or orphan drugs.

Biopharma data showed M&A strength, selective venture capital favoring Phase II, record obesity deals, and significant upfronts flowing toward innovation in China were key in Q3 2025.

The company will also highlight its sustainability strategies and quality solutions at the event.

The European Union aims to become the most attractive place for life science by 2030.

Life sciences CEOs are boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development.

Data from four major pivotal trials will be shared, but AstraZeneca medications and pipeline molecules appear in more than 90 abstracts for the upcoming conference in Berlin.

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.

This paper provides an in-depth overview of the anatomical structure and functional dynamics of renal filtration, secretion, and reabsorption processes that govern drug clearance.

US President Donald Trump made the announcement that AstraZeneca is the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

Pharma accelerates specialized R&D and clinical pipelines via agentic AI and collaboration, while manufacturing scales through CGT 2.0 flexibility, automation, and digitized supply chain security.

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and integrating AI for cancer and metabolic therapies.

The increasing diversity and complexity of injectable drug products is driving innovation.